Intuitive Surgical, Inc. ISRG NDXSPXAI
Company Overview
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Why Investors Should Care
Generates a return on equity of 17.2%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 16.0%.
Net profit has compounded at 18.0% per year over the last five years.
Revenue has grown at a 17.0% CAGR over the past five years.
Maintains a net profit margin of 28.2%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $10.06B (+20.5% YoY); net profit $2.86B.
- Trailing 12 Months Year-on-year growth — revenue +23.0%, earnings +18.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.0%, profit CAGR 18.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.95% |
| 1 Year: | 23.00% |
Compounded Profit Growth
| 5 Years: | 18.03% |
| 1 Year: | 18.80% |
Stock Price Performance
| 1 Year: | -24.68% |
| 6 Months: | -32.09% |
| 3 Months: | -16.75% |
| 1 Month: | -5.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Intuitive Surgical makes the da Vinci surgical-robotics systems and is embedding AI/data analytics to improve minimally invasive surgery.
Robotic-assisted surgery (da Vinci) and endoluminal systems (Ion), with growing AI/data capabilities.
- AI-enabled surgical robotics Intuitive is adding AI and data analytics to da Vinci to enhance surgical insight and outcomes.
- Ion endoluminal robotics Its Ion system extends robotics into minimally invasive lung biopsy.
- Data & learning platform Surgical data feeds analytics that improve technique and training.
- Dominant surgical-robotics franchise with a razor-and-blade model; net ~28%.
- Adding AI/data to deepen its moat and outcomes.
- Premium valuation prices in durable growth.
- Hospital-capex cycles and competition are watch items.
Curated from public filings and analyst commentary; figures are illustrative.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 28.2%.
- Compounding revenue at 17.0% over 5 years.
- Profit CAGR of 18.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 34.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 388.97 | 47.32 | $137.76B | 0.00% | 15.96% | 17.23% | 16.95% | 18.03% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 679.60M | 758.80M | 807.80M | 892.00M | 847.50M | 909.30M | 920.90M | 1.05B | 973.70M | 1.10B | 1.13B | 1.28B | 1.10B | 852.10M | 1.08B | 1.33B | 1.29B | 1.46B | 1.40B | 1.55B | 1.49B | 1.52B | 1.56B | 1.70B | 1.76B | 1.74B | 1.89B | 2.01B | 2.04B | 2.25B | 2.44B | 2.51B | 2.77B |
| Gross Profit | 386.50M | 395.80M | 458.80M | 405.00M | 470.90M | 487.00M | 527.20M | 469.80M | 530.10M | 568.10M | 634.00M | 593.80M | 632.30M | 642.30M | 735.70M | 669.60M | 759.00M | 785.60M | 896.00M | 738.20M | 502.90M | 724.30M | 895.80M | 902.60M | 1.02B | 971.40M | 1.06B | 1.01B | 1.02B | 1.05B | 1.11B | 1.17B | 1.17B | 1.25B | 1.37B | 1.37B | 1.46B | 1.62B | 1.66B | 1.83B |
| Operating Income | 173.80M | 189.90M | - | 179.00M | 245.40M | 256.40M | - | 193.40M | 259.90M | 280.60M | - | 276.70M | 277.40M | 313.30M | - | 252.20M | 359.00M | 365.70M | - | 283.00M | 80.60M | 270.40M | - | 416.80M | 511.20M | 442.60M | - | 408.10M | 397.60M | 398.90M | 387.60M | 463.20M | 465.80M | 469.40M | 567.30M | 577.30M | 578.10M | 743.40M | 759.70M | 855.30M |
| Net Income | 134.50M | 167.30M | 190.00M | 136.40M | 184.50M | 211.00M | 204.00M | 180.80M | 223.00M | 298.60M | -31.50M | 287.60M | 255.30M | 292.50M | 292.50M | 306.50M | 318.30M | 396.80M | 357.70M | 313.50M | 68.00M | 313.90M | 365.20M | 426.30M | 517.20M | 380.50M | 380.60M | 365.60M | 307.80M | 324.00M | 355.30M | 420.80M | 415.70M | 544.90M | 526.90M | 565.10M | 698.40M | 658.40M | 704.40M | 821.50M |
| Diluted EPS | 3.56 | 4.40 | 4.99 | 1.18 | 1.57 | 1.77 | 1.71 | 1.57 | 1.94 | 2.56 | -0.28 | 2.44 | 2.15 | 2.45 | 2.45 | 2.56 | 2.67 | 3.33 | 2.99 | 2.62 | 0.57 | 2.60 | 3.02 | 1.17 | 1.42 | 1.04 | 1.03 | 1.00 | 0.85 | 0.90 | 1.00 | 1.18 | 1.16 | 1.51 | 1.46 | 1.56 | 1.92 | 1.81 | 1.95 | 2.28 |
| R&D Expense | 49.40M | 51.00M | - | 53.20M | 54.70M | 62.60M | - | 73.50M | 84.60M | 83.40M | - | 95.50M | 95.10M | 107.60M | - | 144.00M | 120.80M | 135.90M | - | 147.10M | 143.20M | 155.00M | - | 159.80M | 162.30M | 165.50M | - | 210.50M | 207.30M | 217.10M | 244.90M | 244.40M | 249.40M | 284.50M | 280.10M | 286.00M | 316.20M | 313.30M | 329.40M | 361.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 600.83M | 874.90M | 1.05B | 1.41B | 1.76B | 2.18B | 2.27B | 2.13B | 2.38B | 2.71B | 3.14B | 3.72B | 4.48B | 4.36B | 5.71B | 6.22B | 7.12B | 8.35B | 10.06B |
| Gross Profit | 414.29M | 620.80M | 751.10M | 1.03B | 1.27B | 1.57B | 1.59B | 1.41B | 1.58B | 1.89B | 2.20B | 2.60B | 3.11B | 2.86B | 3.96B | 4.20B | 4.73B | 5.63B | 6.64B |
| Operating Income | 206.74M | 310.80M | 377.40M | 555.20M | 694.80M | 878.10M | 852.50M | 544.80M | 740.00M | 949.70M | 1.06B | 1.20B | 1.37B | 1.05B | 1.82B | 1.58B | 1.77B | 2.35B | 2.95B |
| Net Income | 144.54M | 204.30M | 232.60M | 381.80M | 495.10M | 656.60M | 671.00M | 418.80M | 588.80M | 738.30M | 670.90M | 1.13B | 1.38B | 1.06B | 1.70B | 1.32B | 1.80B | 2.32B | 2.86B |
| Diluted EPS | 3.70 | 5.12 | 5.93 | 9.47 | 12.32 | 15.98 | 16.73 | 11.11 | 5.18 | 6.26 | 5.77 | 9.49 | 3.85 | 2.94 | 4.66 | 3.65 | 5.03 | 6.42 | 7.87 |
| R&D Expense | 48.86M | 79.40M | 95.10M | 116.00M | 140.20M | 170.00M | 167.70M | 178.00M | 197.40M | 239.60M | 328.60M | 418.10M | 557.30M | 595.10M | 671.00M | 879.00M | 998.80M | 1.15B | 1.31B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.47B | 1.81B | 2.39B | 3.06B | 4.06B | 3.95B | 3.96B | 4.91B | 6.49B | 5.78B | 7.85B | 9.73B | 11.17B | 13.55B | 12.97B | 15.44B | 18.74B | 20.46B |
| Total Equity | 589.71M | 888.70M | 1.27B | 1.54B | 2.04B | 2.65B | 3.58B | 3.50B | 3.38B | 4.32B | 5.78B | 4.78B | 6.68B | 8.26B | 9.73B | 11.90B | 11.04B | 13.31B | 16.43B | 17.82B |
| Cash & Equivalents | 34.39M | 122.80M | 194.60M | 221.40M | 279.80M | 465.80M | 553.70M | 782.10M | 600.30M | 714.60M | 1.04B | 648.20M | 857.90M | 1.17B | 1.62B | 1.29B | 1.58B | 2.75B | 2.03B | 3.37B |
| Total Liabilities | - | - | 207.86M | 272.40M | 353.00M | 417.50M | 479.10M | 448.90M | 580.00M | 587.80M | 709.10M | 996.40M | 1.16B | 1.45B | 1.41B | 1.60B | 1.86B | 2.04B | 2.21B | 2.52B |
| Current Liabilities | - | - | 164.52M | 202.80M | 273.80M | 320.60M | 401.60M | 380.90M | 501.20M | 491.90M | 596.50M | 662.80M | 820.60M | 1.03B | 965.20M | 1.15B | 1.42B | 1.66B | 1.75B | 2.01B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 205.69M | 278.20M | 392.20M | 545.80M | 677.60M | 814.20M | 880.00M | 665.10M | 806.20M | 1.09B | 1.14B | 1.17B | 1.60B | 1.48B | 2.09B | 1.49B | 1.81B | 2.42B | 3.03B |
| Investing Cash Flow | -236.40M | -304.50M | -299.50M | -494.30M | -479.00M | -845.70M | 259.00M | -153.90M | -849.50M | -1.28B | 378.70M | -1.05B | -1.15B | -940.60M | -2.46B | 1.37B | -360.10M | -3.27B | 665.80M |
| Financing Cash Flow | 118.85M | 98.00M | -66.20M | 7.70M | -12.40M | 119.20M | -910.60M | -692.40M | 159.10M | 514.40M | -1.91B | 126.30M | -168.40M | -85.70M | 43.00M | -2.57B | -287.60M | 150.90M | -2.36B |
| Share Buybacks | 0 | 0 | 150.00M | 198.60M | 331.80M | 238.30M | 1.11B | 1.00B | 183.70M | 42.50M | 2.27B | 0 | 269.50M | 134.30M | 0 | 2.61B | 416.30M | 0 | 2.30B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 69.0% | 71.0% | 71.4% | 72.9% | 72.5% | 72.1% | 70.4% | 66.3% | 66.2% | 69.9% | 70.2% | 69.9% | 69.4% | 65.6% | 69.3% | 67.4% | 66.4% | 67.5% | 66.0% |
| Operating Margin % | 34.4% | 35.5% | 35.9% | 39.3% | 39.5% | 40.3% | 37.6% | 25.6% | 31.0% | 35.1% | 33.9% | 32.2% | 30.7% | 24.1% | 31.9% | 25.3% | 24.8% | 28.1% | 29.3% |
| Net Margin % | 24.1% | 23.4% | 22.1% | 27.0% | 28.2% | 30.1% | 29.6% | 19.6% | 24.7% | 27.3% | 21.4% | 30.3% | 30.8% | 24.3% | 29.9% | 21.3% | 25.2% | 27.8% | 28.4% |
| ROE % | 16.3% | 16.1% | 15.1% | 18.7% | 18.7% | 18.3% | 19.2% | 12.4% | 13.6% | 12.8% | 14.0% | 16.9% | 16.7% | 10.9% | 14.3% | 12.0% | 13.5% | 14.1% | 16.0% |
| ROCE % | - | 23.7% | 23.5% | 26.2% | 25.3% | 24.0% | 23.9% | 15.8% | 16.8% | 16.1% | 20.8% | 17.1% | 15.8% | 10.3% | 14.7% | 13.7% | 12.8% | 13.8% | 16.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ISRG
ISRG Stock: What Does Its Valuation Imply? - Trefis
<ol><li><a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOdFRvNGRxUzFhRzluS3d5SF96Vmlkcm5lbEpmbGFaUXVScEZrajFVdW1HRVhtVnVPd3VnSVBLOGlWOXJNUjBDZjBKOGhVcklJb2VZdk1uOTNrazVaYlZBNlVVNmhMYW45LVhoN2JJZGd6MFNZOU9SU2ZvazVBRlBzNHJqWVlJa0…
BMO Capital Starts Intuitive Surgical (ISRG) at Outperform - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNM0FRdEVLdnVuLUJqMFZDd3pyM1IwTWxSb0RzMHZZd2g0alplYmVJbWUzd1lPcTlFTGM5NWNYcUlLSTVMQlhLTVFvcEdOOGJVSTBwMG9scjE5RXNnYWVDUHp2akJTb2stTmlhZTlEQmhPeDJMY3BPRU94b3ZUY3paclRYajJTalA3ei1vUk…
The Open Questions On ISRG Stock - Trefis
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQcXd1QU5td0dpamFJYWc3N2dhVjQxWFRNT2x3ZWZoeWxxbWZ6RVFPbkhPX0JPWXJ6QXl0Q2Q3OU91YWlsalFObndPVjlTd015MXgyV01rWlMtRjJVZlJYbW9NQmtJSExvWXNQXzNPcWpuSklLQ2syUGNGMzZxMXJEVkwxTkNJY1ZmZmRvMF…
Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now? - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNdS1ZVG5pSF8wb3JwUFZwRG1hVU9HTkpSNzdFUDlrM0pkRWw2WWI1WVpFWXVxQy1ZQXBjY0Y1S3BtcXJOVDZsRE9XcEM1ek90dERfOGhjOTBlTnhGQ25NeW1nT3BnVzNTd1dKM0gtWi0wWTRoVmtONGgzWHFTdkNJWWZDb1A4Uml1Z2YtZU…
Intuitive Surgical Inc Stock (ISRG) Moved Up by 3.04% on Jul 15: Drivers Behind the Movement - TradingKey
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQzV6TXdvTGRvZmpuSlEzMEsxaGR6eHQyVi00dnhnT25DQmFFWjM0U1RpRUdKRUJyVGVHMjhIY2hNOE9PTFZqTU9iRTc3MHRSY0YzTGNjYVJDRHdUZ29nTW9WYmpFUHBvaElYMGVfMGEyVk1aOXdkYXlqZHFLa01mQ3VnaVZIVW1XZ0hr?o…
Intuitive Surgical’s Stock Has Fallen Over 25% This Year, but Goldman Sachs Still Recommends Investors Buy - NAI500
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQVHlPLXdWa3ZiWGdVUFB6eEZsUkRYOWdBUTdxU0MtZDBFZTNwZGc0OTBtQ1VoMDZGbWtIUjRndldfUks1ME5xSHNJaXNPcER4cXFheWpfZ3hLdjdkbS1OYmQ3R3dQVmFZdkZxX253QWxBM2k3WDVFMi1JWkJRWWNhTGozWVQ3UExQbW5LTW…
ISRG — Frequently Asked Questions
What is the current share price of Intuitive Surgical, Inc. (ISRG)?
As of 2026-07-15 16:51 PDT, Intuitive Surgical, Inc. (ISRG) trades at $388.97 on NasdaqGS. Its 52-week range is $379.50 to $592.85.
What is the market capitalisation of ISRG?
Intuitive Surgical, Inc. (ISRG) has a market capitalisation of $137.76B on NasdaqGS.
What is the P/E ratio of ISRG?
ISRG trades at a trailing price-to-earnings (P/E) ratio of 47.32. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 8.34.
What is the return on equity (ROE) of ISRG?
ISRG has a return on equity (ROE) of 17.23%. Its return on capital employed (ROCE) is 15.96%.
Is ISRG a good stock to buy?
This page provides a data-driven analysis of Intuitive Surgical, Inc. (ISRG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.